Overview

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

Status:
COMPLETED

Trial end date:
2025-09-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Acetaminophen
Loratadine